Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0000318154
$438.34
-0.14% · delayed ~15 min
Last price from Oct 21, 2026
$236.18B market value
From AMGEN INC's FY2025 10-K, filed Feb 13, 2026 · read the filing
AMGEN develops and makes medicines. It took in $36.75B last year, which makes it a large company. Of every dollar it sells, about 21 cents is left as profit.
The financial picture is led by profitability and accounting, with growth and debt worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 3 insiders, not under a pre-arranged plan.
$4.1M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From AMGEN INC's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$4.09B → $7.71B
Profit margin
12.2% → 21.0%
Earnings per share
$7.62 → $14.31
Capital spending
$1.10B → $1.86B
Measured against FY2024, from the 10-K filed Feb 13, 2026
Improved: +88.5%
$4.09B to $7.71BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
AMGN fell 0.14% on the latest quote. The average Health Care company tracked here moved +1.61%, and the S&P 500 −1.04%. That is 1.7 points below its sector and 0.9 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 13% a year for the next 10 years. Over the last 10 years it shrank by about 1% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 21 cents of every dollar of sales as profit, earning $7.71B last year.
Slowly. Sales grew 10.0% last year.
Manageable, but notable. Clearing its debt would take about 4.6 years of cash flow. For every $1 it owes, it owns $1.11 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 66 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 51% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $7.71B and generated $9.96B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 13, 2026Filing for FY2025 | FY202410-K · Feb 14, 2025Filing for FY2024 | FY202310-K · Feb 14, 2024Filing for FY2023 | FY202210-K · Feb 14, 2024Filing for FY2022 | FY202110-K · Feb 14, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B | +10.0% |
| Cost of revenue | $12.04B | $12.86B | $8.45B | $6.41B | $6.45B | −6.4% |
| Gross profit | $24.71B† | $20.57B† | $19.74B† | $19.92B† | $19.52B† | +20.2% |
| Gross marginGross profit ÷ revenueWhat is this? | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% | +5.7 pts |
| Selling, general and administrative | $7.05B | $7.10B | $6.18B | $5.41B | $5.37B | −0.6% |
| Operating income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B | +25.1% |
| Operating marginOperating income ÷ revenueWhat is this? | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% | +3.0 pts |
| Interest expense | $2.75B | $3.15B | $2.88B | $1.41B | $1.20B | −12.7% |
| Income before tax | $8.98B | $4.61B | $7.86B | $7.35B | $6.70B | +94.7% |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B | +88.5% |
| Net marginNet income ÷ revenueWhat is this? | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | +8.7 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $14.31 | $7.62 | $12.55 | $12.27 | $10.56 | +87.9% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| AMGNAMGEN INC · this page | 8.0/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 2,000 shares at $412.57 ($825.1K)
Holds 6,404 shares after this filing.
Exercised stock options — 1,252 shares at $162.60 ($203.6K)
Holds 7,656 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +9.5% · Operating margin +6.0 pts · Profit +65.9% — against Q2 FY2025
Read the filingPublished results
Read the filingWrite down why you are following AMGEN INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 42 subsidiaries named in its 10-K, incorporated across 16 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from AMGN's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 13, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 7.0 | 8/9 | 10-K, filed Feb 13, 2026 |
| FY2024 | 8.0 | 6/9 | 10-K, filed Feb 14, 2025 |
| FY2023 | 7.0 | 6/9 | 10-K, filed Feb 14, 2024 |
| FY2022 | 7.0 | 6/9 | 10-K, filed Feb 9, 2023 |
| FY2021 | 7.0 | 5/9 | 10-K, filed Feb 16, 2022 |
| FY2020 | 7.0 | 6/9 | 10-K, filed Feb 9, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.13
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.26
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +8.8 pts
12.2% to 21.0%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +87.9%
$7.62 to $14.31Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Changed: +69.5%
$1.10B to $1.86BCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +20.2%
$20.57B to $24.71BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +25.1%
$7.26B to $9.08BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +5.7 pts
61.5% to 67.2%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: -22.1%
$10.39B to $8.10BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -23.8%
$11.97B to $9.13BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +10.0%
$33.42B to $36.75BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +3.0 pts
21.7% to 24.7%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: -11.6%
$56.55B to $50.01BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Changed: +6.0%
$4.83B to $5.12BNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Improved: +65.9%
$1.43B to $2.38BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +8.0 pts
15.6% to 23.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +65.1%
$2.66 to $4.39Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +74.3%
$8.03B to $13.99BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +17.4%
$6.17B to $7.24BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +32.3%
$2.66B to $3.51BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +4.8 pts
67.2% to 72.0%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +6.0 pts
28.9% to 35.0%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +9.5%
$9.18B to $10.05BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +16.7%
$8.62B to $10.05BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +23.3%
$5.87B to $7.24BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +31.8%
$2.67B to $3.51BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +30.6%
$1.82B to $2.38BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +3.9 pts
68.2% to 72.0%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +4.0 pts
30.9% to 35.0%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +30.3%
$3.37 to $4.39Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +16.2%
$12.04B to $13.99BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +2.5 pts
21.1% to 23.6%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 10% and 15%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 42 analysts covering this company, as of . Their views, not this site's.
Of 42 analysts publishing on this company, 6 say strong buy, 12 say buy, 20 say hold, 3 say sell and 1 say strong sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.6% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 26.7x — investors pay $26.7 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 10.0% |
| 21.0% |
| 30.63x |
| 9.46x |
| ABBVAbbVie Inc. | 7.0/10 | 8/9 | 8.6% | 6.9% | 119.13x | -41.97x |
|---|
| GILDGILEAD SCIENCES, INC. | 9.0/10 | 8/9 | 2.4% | 28.9% | 22.92x | 1.60x |
|---|
| VRTXVERTEX PHARMACEUTICALS INC / MA | 8.7/10 | 6/8 | 8.9% | 32.9% | 34.38x | 0.37x |
|---|
| MRNAModerna, Inc. | 6.0/10 | 3/9 | -39.9% | -145.2% | — | 0.43x |
|---|
| REGNREGENERON PHARMACEUTICALS, INC. | 8.7/10 | 6/8 | 1.0% | 31.4% | 19.02x | 0.30x |
|---|
| Median of peers | 8.7/10 | — | 2.4% | 28.9% | 28.65x | 0.37x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 1,252 shares at $416.43 ($521.4K)
Holds 6,404 shares after this filing.
Was granted or awarded shares — 730 shares
Holds 5,080 shares after this filing.
Was granted or awarded shares — 64 shares
Holds 5,876 shares after this filing.
Was granted or awarded shares — 103 shares
Holds 12,990 shares after this filing.
Was granted or awarded shares — 85 shares
Holds 7,486 shares after this filing.
Exercised stock options — 1,970 shares at $177.46 ($349.6K)
Holds 9,310 shares after this filing.
Sold on the open market — 1,970 shares at $402.16 ($792.3K)
Holds 7,340 shares after this filing.
Exercised stock options — 1,000 shares at $177.31 ($177.3K)
Holds 8,340 shares after this filing.
Sold on the open market — 1,000 shares at $402.16 ($402.2K)
Holds 7,340 shares after this filing.
Exercised stock options — 2,069 shares at $162.60 ($336.4K)
Holds 14,531 shares after this filing.
Sold on the open market — 2,069 shares at $402.54 ($832.9K)
Holds 12,462 shares after this filing.
Exercised stock options — 1,821 shares at $177.46 ($323.2K)
Holds 14,283 shares after this filing.
Sold on the open market — 1,821 shares at $402.54 ($733.0K)
Holds 12,462 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 1,252 shares ($516.8K) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 2,000 shares ($828.4K) on or after .
Shares originally obtained via Stock award.
Filed notice to sell 2,670 shares ($1.2M) on or after .
Shares originally obtained via Cashless Stock Option Exercise.
Filed notice to sell 3,890 shares ($1.6M) on or after .
Shares originally obtained via Acquired as compensation -- Stock Options.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Disclosed a material cybersecurity incident
Held a shareholder vote
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q1 FY2026
Revenue +5.8% · Operating margin +16.5 pts · Operating income +126.3% — against Q1 FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingProxy statement for a shareholder meeting
Read the filingSigned a material agreement
Read the filingAnnual report for FY2025
Revenue +10.0% · Operating margin +3.0 pts · Profit +88.5% — against FY2024
Read the filingPublished results
Read the filingTerminated a material agreement
Read the filingQuarterly report for Q3 FY2025
Revenue +12.4% · Operating margin +2.4 pts · Gross profit +24.7% — against Q3 FY2024
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2025
Revenue +9.4% · Operating margin +6.2 pts · Profit +92.0% — against Q2 FY2024
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2025
Revenue +9.4% · Operating margin +1.1 pts · Profit turned positive — against Q1 FY2024
Read the filingPublished results
Read the filingThe first 40 of 42. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-13. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Yahoo ·
Amgen (AMGN) Gains As Market Dips: What You Should Know
Yahoo ·
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?
Yahoo ·
Dow Jones Top Movers Today: PG and JNJ Lead Gainers, CAT and AMZN Lead Losers
ChartMill ·
Dow Jones Top Movers: Gainers and Losers on October 22, 2026
ChartMill ·
BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.
Yahoo ·
AstraZeneca (LSE:AZN) Reports Positive Phase III Results In Eosinophilic Esophagitis
Yahoo ·
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Yahoo ·
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?
Yahoo ·
What Changed In Amgen's Story?
Yahoo ·
Amgen and AstraZeneca report Phase III Tezspire data for EoE
Yahoo ·
Biotech ETF (BBH) Hits New 52-Week High
Yahoo ·
Primary sources and further research